Much progress in clinical cancer chemoprevention has occurred since the first National Cancer Institute (NCI) workshop devoted to Chemoprevention Clinical Trials— Problems and Solutions in May 1984.<sup>9   Chemoprevention Clinical Trials—Problems and Solutions Bethesda, MD: US Department of Health and Human Services (November 1984).  NIH Publication No. 85-2715..

Haga clic aquí para ir a la sección de Referencias, 16 DeWys W.D., Greenwald P. A recent emphasis in the Prevention Program of the National Cancer Institute Semin Oncol 1983 ;  10 : 360

Haga clic aquí para ir a la sección de Referencias</sup> Today, there is a well-established drug development program in the NCI Division of Cancer Prevention, many prevention-oriented Investigational New Drug Applications are on file at the Food and Drug Administration (FDA), a dedicated group of researchers is committed to translating the promising findings of preclinical prevention studies into human trials, one agent has been specifically FDA approved for the risk reduction or prevention of cancer, and increasing levels of private investment indicate public confidence that cancer can be prevented.<sup>19 Fisher B., Costantino J.P., Wickerham D.L. , y al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 1998 ;  90 : 1371-1388  [cross-ref]

Haga clic aquí para ir a la sección de Referencias, 47 Kelloff G.J., Hawk E.T., Karp J.E. , y al. Progress in clinical chemoprevention Semin Oncol 1997 ;  24 : 241-252

Haga clic aquí para ir a la sección de Referencias, 48 Kelloff G.J., Johnson J.R., Crowell J.A. , y al. Approaches to the development and marketing approval of drugs that prevent cancer Cancer Epidemiol Biomarkers Prev 1995 ;  4 : 1-10

Haga clic aquí para ir a la sección de Referencias</sup> Nevertheless, a brief review of the proceedings from the 1984 workshop reveals that the challenges involved in translating the promise of cancer prevention into a clinical reality remain and indeed may now be even more complex.<sup>3 Baron J.A. Compliance issues/biological markers Chemoprevention Clinical Trials—Problems and Solutions Bethesda, MD: US Department of Health and Human Services (November 1984).  44-48 NIH Publication No. 85-2715..

Haga clic aquí para ir a la sección de Referencias, 92 Sestili M.A. Safety considerations in the conduct of chemoprevention trials Chemoprevention Clinical Trials—Problems and Solutions Bethesda, MD: US Department of Health and Human Services (November 1984).  83-86 NIH Publication No. 85-2715..

Haga clic aquí para ir a la sección de Referencias, 99 Tangrea J.A. Recruitment: A perspective for multicenter clinical trials Chemoprevention Clinical Trials—Problems and Solutions Bethesda, MD: US Department of Health and Human Services (November 1984).  30-32 NIH Publication No. 85-2715..

Haga clic aquí para ir a la sección de Referencias</sup>